Active substances: Isotretinoin
Relapse occurred in 16. Relapses were more common in females with polycystic ovarian disease.
These relapses controlled with topical therapy alone or combined with oral antibiotics.
The relapse rate observed by us was lower than that of above mentioned studies. Table 3 Open in a separate window In a study by Amichai et al.
Patients at increased risk for early relapse included younger patients with acne of relatively recent onset, those with truncal acne, and women with polycystic ovary syndrome.
In our study, relapse rate had not any relation with patient's weight, age, and anatomical location of lesions. Safety was assessed during the study by the reporting of adverse events.
The most common side-effects in our study were mild cheilitis in 93 patients 66.
The observed side-effects were mild, and only 6 patients discontinued study medication because of severe adverse events.
Isotretinoin can cause variant side-effects; mucocutaneous side-effects are the most common, experienced by virtually all patients. Epistaxis only seen in conventional group but in our study. Elevated liver function test results, and increase in serum lipid profiles was mild, and usually returned to normal within 6-8 weeks, despite continuation of treatment.
The present study showed that low dose 20 mg daily isotretiinoin represents a well-tolerated and efficient alternative to the standard 0.
The only pitfall is it is longer than 10 months duration of treatment period.